Report on Epilepsy Ireland proposals on access to Free Travel expected in coming weeks
Read about a recent update regarding Epilepsy Ireland's longstanding campaign.
Read about a recent update regarding Epilepsy Ireland's longstanding campaign.
November 7th to 13th is #MedSafetyWeek - do you know how to report a side effect from medication?
Read the fantastic poem from Isabel in the news section of our website.
Epilepsy Ireland has been notified by the Health Products Regulatory Authority (HPRA) that further issues are expected with the supply of the Anti-Seizure medication, Rivotril (Clonazepam).
In September, manufacturing issues created a shortage of the medication and led to difficulties for many patients in having their prescriptions filled. Although supply had returned to normal in recent weeks, it now appears that further shortages are likely.
Read more about an important development regarding this Anti-Seizure medication.
Find out why this epic Cycle has been rightly recognised as part of the annual awards!
Read the statement we have issued for SUDEP Action Day 2022.
Epilepsy Ireland have been contacted by UCB, manufacturers of the Anti-Seizure Medication Vimpat (Lacosamide), informing us that their patent exclusivity for the medication has now expired.
This means that other pharmaceutical manufacturers can bring forward generic versions of this medication to be marketed in Ireland.
The National Centre for Pharmacoeconomics (NCPE) have updated Epilepsy Ireland that they have issued a positive recommendation regarding the potential reimbursement of the anti-seizure medication, Cenobamate.
The medication has been indicated for use in adults living with focal-onset seizures and has posted positive clinical trial results. Epilepsy Ireland made a submission to the NCPE in July supporting reimbursement of the medication.
At a time when we have experienced record demand for our services, we have also seen a 50% drop in fundraised income. We need your support this Rose Week.